Biased Ligands. Better Drugs.

TRV130 Phase 2 bunionectomy trial

TRV130, a G Protein-biased Ligand of the ยต-opioid Receptor, Demonstrates Analgesic Efficacy Following Bunionectomy in an Adaptive Phase 2 Study

Eugene R. Viscusi, MD, Lynn Webster, MD, Michael Kuss, BS, Stephen Daniels, DO, James A. Bolognese, MS, Seth Zuckerman, MS, David G. Soergel, MD, Ruth Ann Subach, PharmD, Emily Cook, BA, Franck Skobieranda, MD.

View PDF

Copyright © Trevena, Inc.